Treatment of Temporomandibular Joint Syndrome in Arthrogenous Temporomandibular Disorder
Clinical Scenario
This protocol is for patients with temporomandibular joint syndrome whose underlying aetiology is arthrogenous temporomandibular disorder (arthrogenous TMD) — a joint-driven subtype with specific treatment implications.
Clinical note: Neuromodulatory agents are not appropriate for arthrogenous TMD sub-diagnoses and should not be used in this patient group.
First-Line Management Approach
The recommended first-line strategy is a supported self-management (SSM) plan, developed collaboratively between the patient and their primary care practitioner. The plan draws on several self-directed therapeutic modalities — the complete set of components, their sequence, and the full clinical algorithm are detailed in the structured protocol.
Treatment Goals
- Reduction in pain intensity
- Reduction in pain-related disability
References
- Neuromodulatory agents have not been shown to be beneficial for arthrogenous TMD sub diagnoses and their use in such situations is not advocated.
- All individuals diagnosed with painful TMD (any sub diagnosis) should be actively involved in the development of a supported self-management (SSM) plan with their primary care practitioner.
- SSM has been shown to support reduction in pain intensity and pain related disability with no reported adverse effects, suggesting favorable risk: benefit ratio, for low economic cost.
View source ↗